브루셀라병 백신 시장 : 유형별, 백신별, 동물 유형별, 최종사용자별 - 세계 기회 분석 및 산업 예측(2024-2033년)

Brucellosis Vaccines Market By Type , By Vaccine By Animal Type By End User : Global Opportunity Analysis and Industry Forecast, 2024-2033

US $ 4,425 ￦ 6,154,000

PDF (Business License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 5회 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 2명 이상이 이용할 경우, 추가 요금을 지불하여 라이선스 업그레이드로 최대 5명까지 이용 가능합니다.

US $ 7,412 ￦ 10,308,000

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

PDF 보고서 및 Excel 데이터를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 보고서 업데이트 서비스가 무료로 제공됩니다.

한글목차

브루셀라병 백신 시장은 2023년 2억 달러로 평가되며, 2024-2033년 연평균 6.4% 성장하여 2033년에는 4억 달러에 달할 것으로 예상됩니다.

브루셀라병 백신은 브루셀라균에 의한 인수공통전염병인 브루셀라병의 예방과 통제에 사용되는 중요한 도구입니다. 이 질병은 소, 양, 염소 등 다양한 가축을 감염시켜 유산, 번식력 저하 등 번식 장애를 일으켜 농업 부문에 막대한 경제적 손실을 가져옵니다. 사람의 경우 브루셀라병은 독감과 같은 가벼운 증상부터 심각한 만성 증상까지 다양한 증상을 유발할 수 있습니다. 가축에 대한 백신 접종은 동물에서 사람으로의 브루셀라병 감염을 감소시키는 핵심이며, 공중 보건과 식품 안전에 중요한 역할을 합니다.

세계 브루셀라병 백신 시장의 성장은 특히 농업 활동이 활발한 지역에서 가축의 브루셀라병 발병률 증가와 브루셀라병 예방을 위한 백신 접종의 중요성에 대한 농업 종사자 및 가축 소유자의 인식이 높아짐에 따라 이루어지고 있습니다. 세계 최고의 의료 연구 센터인 미국 국립보건원(NIH)의 조사에 따르면, 브루셀라병은 인수공통전염병 중 가장 흔한 질병 중 하나로 연간 50만 명의 환자가 발생합니다. 육류 및 유제품에 대한 세계 수요가 증가함에 따라 브루셀라증과 같은 질병으로부터 가축을 보호해야 할 필요성이 높아지면서 브루셀라병 백신 시장을 더욱 견인하고 있습니다. 또한, 브루셀라증은 인수공통전염병으로 사람에게도 감염될 수 있기 때문에 사람의 건강을 보호하기 위해 가축의 질병을 통제하는 것에 대한 관심이 높아지고 있으며, 이는 백신 수요를 촉진하고 있습니다. 또한, 특히 브루셀라병이 공중보건상 중요한 문제인 국가에서는 지역 및 국가 차원의 백신 접종 캠페인이 활발히 진행되고 있어 시장 성장에 크게 기여하고 있습니다. 또한 인간, 동물, 환경 건강의 상호 연관성에 초점을 맞춘 원헬스(One Health) 개념의 중요성이 브루셀라병 백신 시장에 영향을 미치고 있습니다. 이러한 총체적 접근 방식은 특히 브루셀라병이 유행하는 지역에서 동물과 인간 모두에서 브루셀라병을 퇴치하기 위한 통합적인 노력을 기울이고 있습니다. 그러나 새롭고 효과적인 브루셀라병 백신을 개발하는 데 드는 높은 비용이 세계 시장 성장을 가로막고 있습니다. 또한, 유전적 변이로 인한 브루셀라균의 백신 내성 균주의 출현은 기존 백신의 효능을 떨어뜨려 시장 성장을 크게 저해하고 있습니다. 반면, 보다 효과적이고 안전한 백신의 개발 등 백신 기술의 발전은 질병 예방 효과를 향상시킴으로써 시장 성장에 기여하고 있습니다. 또한, 생명공학의 발전은 재조합 DNA 기술 및 기타 분자 기술의 활용과 같은 백신 제조의 혁신을 촉진하고 있습니다. 이러한 혁신은 브루셀라병 백신의 효능과 안전성을 향상시키고, 더 쉽게 접근하고 확장할 수 있도록 돕고 있습니다.

세계 브루셀라병 백신 산업은 유형, 백신, 동물 유형, 최종사용자, 지역으로 구분됩니다. 유형별로 시장은 RBS1, S19, B19로 나뉩니다. 백신은 DNA 백신, 서브유닛 백신, 벡터 백신, 재조합 백신으로 나뉩니다. 동물 유형별로 소, 양, 염소로 세분화됩니다. 최종사용자에 따라 동물 병원 및 클리닉, 동물 진료소, 기타로 세분화됩니다. 지역별로는 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카로 분석됩니다.

주요 조사 결과

유형별로는 RBS1 부문이 2023년 시장 점유율 1위를 차지했습니다.

백신별로는 DNA 백신 부문이 2023년 시장의 주요 주주였습니다.

동물 유형별로는 소가 2023년 주요 부문으로 부상했습니다.

최종사용자별로는 동물병원 및 클리닉 부문이 2023년 가장 큰 점유율을 차지했습니다.

지역별로는 북미가 2023년 지배적인 위치를 차지했지만, 아시아태평양이 예측 기간 동안 가장 높은 CAGR을 기록할 것으로 예상됩니다.

본 보고서의 커스터마이징 가능성(추가 비용 및 일정이 필요합니다.)

• 제품/부문별 시장 세분화
• 주요 기업의 신제품 개발/제품 매트릭스
• 규제 가이드라인
• 고객의 관심사에 따른 추가 기업 개요
• 국가별 또는 지역별 추가 분석 - 시장 규모 및 전망
• 기업 개요 확대 목록
• 과거 시장 데이터
• 주요 진입기업 세부 정보(위치, 연락처, 공급업체/벤더 네트워크 등 포함, 엑셀 형식)

목차

제1장 소개

제2장 주요 요약

제3장 시장 상황

• 시장 정의와 범위
• 주요 조사 결과
  • 주요 투자 기회
  • 주요 성공 전략
• Porter's Five Forces 분석
• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회

제4장 브루셀라병 백신 시장 : 유형별

• 시장 개요
• RBS1
• S19
• B19

제5장 브루셀라병 백신 시장 : 백신별

• 시장 개요
• DNA 백신
• 아단위 백신
• 벡터 백신
• 재조합 백신

제6장 브루셀라병 백신 시장 : 동물 유형별

• 시장 개요
• 소
• 양
• 염소

제7장 브루셀라병 백신 시장 : 최종사용자별

• 시장 개요
• 동물 병원과 클리닉
• 동물 케어 센터
• 기타

제8장 브루셀라병 백신 시장 : 지역별

• 시장 개요
• 북미
  • 주요 시장 동향과 기회
  • 미국의 브루셀라병 백신 시장
  • 캐나다의 브루셀라병 백신 시장
  • 멕시코의 브루셀라병 백신 시장
• 유럽
  • 주요 시장 동향과 기회
  • 독일의 브루셀라병 백신 시장
  • 프랑스의 브루셀라병 백신 시장
  • 영국의 브루셀라병 백신 시장
  • 이탈리아의 브루셀라병 백신 시장
  • 스페인의 브루셀라병 백신 시장
  • 기타 유럽의 브루셀라병 백신 시장
• 아시아태평양
  • 주요 시장 동향과 기회
  • 일본의 브루셀라병 백신 시장
  • 중국의 브루셀라병 백신 시장
  • 호주의 브루셀라병 백신 시장
  • 인도의 브루셀라병 백신 시장
  • 한국의 브루셀라병 백신 시장
  • 기타 아시아태평양의 브루셀라병 백신 시장
• 라틴아메리카, 중동 및 아프리카
  • 주요 시장 동향과 기회
  • 브라질의 브루셀라병 백신 시장
  • 사우디아라비아의 브루셀라병 백신 시장
  • 남아프리카공화국의 브루셀라병 백신 시장
  • 기타 라틴아메리카, 중동 및 아프리카의 브루셀라병 백신 시장

제9장 경쟁 상황

• 소개
• 주요 성공 전략
• 주요 10개 기업 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝(2023년)

제10장 기업 개요

• Ceva Poultry
• Colorado Serum Company
• Creative Biolabs
• CZ Vaccines
• Fivet Animal Health
• Hester Biosciences Limited
• Indian Immunologicals Ltd
• Jordan Bio-industries Center
• Laboratories Tornel
• Merck And Co., Inc.

ksm

영문 목차

영문목차

The brucellosis vaccines market was valued at $0.2 billion in 2023, and is projected to reach $0.4 billion by 2033, growing at a CAGR of 6.4% from 2024 to 2033.

Brucellosis vaccine is a critical tool used in the prevention and control of brucellosis, a zoonotic bacterial infection caused by Brucella species. This disease affects various livestock, including cattle, sheep, and goats, leading to reproductive failures such as abortions, reduced fertility, and significant economic losses in the agricultural sector. In humans, brucellosis can cause a range of symptoms, from mild flu-like illness to severe, chronic conditions. Vaccination of livestock is a cornerstone in reducing the transmission of Brucella from animals to humans, thus playing a vital role in public health and food safety.

The growth of the global brucellosis vaccines market is driven by rise in incidence of brucellosis in livestock, particularly in regions with significant agricultural activity, and increase in awareness among farmers and livestock owners about the importance of vaccination in preventing brucellosis. According to a study published by the National Institutes of Health-one of the world's foremost medical research centers-brucellosis is one the most common zoonotic diseases affecting 500,000 cases annually. As the global demand for meat and dairy products grows, there is a corresponding increase in the need to protect livestock from diseases like brucellosis, further driving the brucellosis vaccine market. Moreover, with brucellosis being a zoonotic disease that can be transmitted to humans, there is an increasing focus on controlling the disease in animals to protect human health, which, in turn, fosters the demand for vaccines. Furthermore, increase in trend of regional and national vaccination campaigns, particularly in countries where brucellosis is a significant public health issue, is notably contributing toward the market growth. In addition, emphasis on the One Health concept, which focuses on the interconnectedness of human, animal, and environmental health, is influencing the brucellosis vaccination market. This holistic approach is leading to integrated efforts to control brucellosis in both animals and humans, particularly in regions where the disease is endemic. However, high cost associated with development of new and effective brucellosis vaccines is hampering the growth of the global market. In addition, the emergence of vaccine-resistant strains of Brucella due to genetic variability has reduced the effectiveness of existing vaccines, which significantly restrained the market growth. On the contrary, advancements in vaccine technology, such as the development of more effective and safer vaccines, are contributing to market growth by improving the efficacy of disease control measures. Moreover, advances in biotechnology are driving innovations in vaccine production, including the use of recombinant DNA technology and other molecular techniques. These innovations are enhancing the efficacy and safety of brucellosis vaccines, making them more accessible and scalable.

The global brucellosis vaccines industry is segmented into type, vaccine, animal type, end user, and region. By type, the market is divided into RBS1, S19, and B19. As per vaccine, it is segregated into DNA vaccine, subunit vaccine, vector vaccine, and recombinant vaccine. By animal type, it is fragmented into cattle, sheep, and goat. Depending on end user, it is fragmented into veterinary hospitals & clinics, animal care centers, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By type, the RBS1 segment dominated the market share in 2023.

As per vaccine, the DNA vaccine segment was the major shareholder in the market in 2023.

On the basis of animal type, cattle emerged as the leading segment in 2023.

Depending on end user, the veterinary hospitals & clinics segment garnered the largest share in 2023.

Region wise, North America held the dominant position in 2023; however, Asia-Pacific is expected to register highest CAGR during the forecast period.

Competition Analysis

Competitive analysis and profiles of the major players in the global brucellosis vaccines market include Ceva Poultry, Colorado Serum Company, Creative Biolabs, CZ Vaccines, Fivet Animal Health, Hester Biosciences Limited, Indian Immunologicals Ltd, Jordan Bio-industries Center, Laboratories Tornel, and Merck & Co., Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain a strong foothold in the global market.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Market share analysis of players by products/segments
• New Product Development/ Product Matrix of Key Players
• Regulatory Guidelines
• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Expanded list for Company Profiles
• Historic market data
• Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Type

• RBS1
• S19
• B19

By Vaccine

• DNA Vaccine
• Subunit Vaccine
• Vector Vaccine
• Recombinant Vaccine

By Animal Type

• Cattle
• Sheep
• Goat

By End User

• Veterinary Hospitals and Clinics
• Animal Care Centers
• Other

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players:

• Ceva Poultry
• Colorado Serum Company
• Creative Biolabs
• CZ Vaccines
• Fivet Animal Health
• Hester Biosciences Limited
• Indian Immunologicals Ltd
• Jordan Bio-industries Center
• Laboratories Tornel
• Merck & Co., Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report Description
• 1.2. Key Market Segments
• 1.3. Key Benefits
• 1.4. Research Methodology
  • 1.4.1. Primary Research
  • 1.4.2. Secondary Research
  • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

• 3.1. Market Definition and Scope
• 3.2. Key Findings
  • 3.2.1. Top Investment Pockets
  • 3.2.2. Top Winning Strategies
• 3.3. Porter's Five Forces Analysis
  • 3.3.1. Bargaining Power of Suppliers
  • 3.3.2. Threat of New Entrants
  • 3.3.3. Threat of Substitutes
  • 3.3.4. Competitive Rivalry
  • 3.3.5. Bargaining Power among Buyers
• 3.4. Market Dynamics
  • 3.4.1. Drivers
  • 3.4.2. Restraints
  • 3.4.3. Opportunities

CHAPTER 4: BRUCELLOSIS VACCINES MARKET, BY TYPE

• 4.1. Market Overview
  • 4.1.1 Market Size and Forecast, By Type
• 4.2. RBS1
  • 4.2.1. Key Market Trends, Growth Factors and Opportunities
  • 4.2.2. Market Size and Forecast, By Region
  • 4.2.3. Market Share Analysis, By Country
• 4.3. S19
  • 4.3.1. Key Market Trends, Growth Factors and Opportunities
  • 4.3.2. Market Size and Forecast, By Region
  • 4.3.3. Market Share Analysis, By Country
• 4.4. B19
  • 4.4.1. Key Market Trends, Growth Factors and Opportunities
  • 4.4.2. Market Size and Forecast, By Region
  • 4.4.3. Market Share Analysis, By Country

CHAPTER 5: BRUCELLOSIS VACCINES MARKET, BY VACCINE

• 5.1. Market Overview
  • 5.1.1 Market Size and Forecast, By Vaccine
• 5.2. DNA Vaccine
  • 5.2.1. Key Market Trends, Growth Factors and Opportunities
  • 5.2.2. Market Size and Forecast, By Region
  • 5.2.3. Market Share Analysis, By Country
• 5.3. Subunit Vaccine
  • 5.3.1. Key Market Trends, Growth Factors and Opportunities
  • 5.3.2. Market Size and Forecast, By Region
  • 5.3.3. Market Share Analysis, By Country
• 5.4. Vector Vaccine
  • 5.4.1. Key Market Trends, Growth Factors and Opportunities
  • 5.4.2. Market Size and Forecast, By Region
  • 5.4.3. Market Share Analysis, By Country
• 5.5. Recombinant Vaccine
  • 5.5.1. Key Market Trends, Growth Factors and Opportunities
  • 5.5.2. Market Size and Forecast, By Region
  • 5.5.3. Market Share Analysis, By Country

CHAPTER 6: BRUCELLOSIS VACCINES MARKET, BY ANIMAL TYPE

• 6.1. Market Overview
  • 6.1.1 Market Size and Forecast, By Animal Type
• 6.2. Cattle
  • 6.2.1. Key Market Trends, Growth Factors and Opportunities
  • 6.2.2. Market Size and Forecast, By Region
  • 6.2.3. Market Share Analysis, By Country
• 6.3. Sheep
  • 6.3.1. Key Market Trends, Growth Factors and Opportunities
  • 6.3.2. Market Size and Forecast, By Region
  • 6.3.3. Market Share Analysis, By Country
• 6.4. Goat
  • 6.4.1. Key Market Trends, Growth Factors and Opportunities
  • 6.4.2. Market Size and Forecast, By Region
  • 6.4.3. Market Share Analysis, By Country

CHAPTER 7: BRUCELLOSIS VACCINES MARKET, BY END USER

• 7.1. Market Overview
  • 7.1.1 Market Size and Forecast, By End User
• 7.2. Veterinary Hospitals And Clinics
  • 7.2.1. Key Market Trends, Growth Factors and Opportunities
  • 7.2.2. Market Size and Forecast, By Region
  • 7.2.3. Market Share Analysis, By Country
• 7.3. Animal Care Centers
  • 7.3.1. Key Market Trends, Growth Factors and Opportunities
  • 7.3.2. Market Size and Forecast, By Region
  • 7.3.3. Market Share Analysis, By Country
• 7.4. Other
  • 7.4.1. Key Market Trends, Growth Factors and Opportunities
  • 7.4.2. Market Size and Forecast, By Region
  • 7.4.3. Market Share Analysis, By Country

CHAPTER 8: BRUCELLOSIS VACCINES MARKET, BY REGION

• 8.1. Market Overview
  • 8.1.1 Market Size and Forecast, By Region
• 8.2. North America
  • 8.2.1. Key Market Trends and Opportunities
  • 8.2.2. Market Size and Forecast, By Type
  • 8.2.3. Market Size and Forecast, By Vaccine
  • 8.2.4. Market Size and Forecast, By Animal Type
  • 8.2.5. Market Size and Forecast, By End User
  • 8.2.6. Market Size and Forecast, By Country
  • 8.2.7. U.S. Brucellosis Vaccines Market
    • 8.2.7.1. Market Size and Forecast, By Type
    • 8.2.7.2. Market Size and Forecast, By Vaccine
    • 8.2.7.3. Market Size and Forecast, By Animal Type
    • 8.2.7.4. Market Size and Forecast, By End User
  • 8.2.8. Canada Brucellosis Vaccines Market
    • 8.2.8.1. Market Size and Forecast, By Type
    • 8.2.8.2. Market Size and Forecast, By Vaccine
    • 8.2.8.3. Market Size and Forecast, By Animal Type
    • 8.2.8.4. Market Size and Forecast, By End User
  • 8.2.9. Mexico Brucellosis Vaccines Market
    • 8.2.9.1. Market Size and Forecast, By Type
    • 8.2.9.2. Market Size and Forecast, By Vaccine
    • 8.2.9.3. Market Size and Forecast, By Animal Type
    • 8.2.9.4. Market Size and Forecast, By End User
• 8.3. Europe
  • 8.3.1. Key Market Trends and Opportunities
  • 8.3.2. Market Size and Forecast, By Type
  • 8.3.3. Market Size and Forecast, By Vaccine
  • 8.3.4. Market Size and Forecast, By Animal Type
  • 8.3.5. Market Size and Forecast, By End User
  • 8.3.6. Market Size and Forecast, By Country
  • 8.3.7. Germany Brucellosis Vaccines Market
    • 8.3.7.1. Market Size and Forecast, By Type
    • 8.3.7.2. Market Size and Forecast, By Vaccine
    • 8.3.7.3. Market Size and Forecast, By Animal Type
    • 8.3.7.4. Market Size and Forecast, By End User
  • 8.3.8. France Brucellosis Vaccines Market
    • 8.3.8.1. Market Size and Forecast, By Type
    • 8.3.8.2. Market Size and Forecast, By Vaccine
    • 8.3.8.3. Market Size and Forecast, By Animal Type
    • 8.3.8.4. Market Size and Forecast, By End User
  • 8.3.9. UK Brucellosis Vaccines Market
    • 8.3.9.1. Market Size and Forecast, By Type
    • 8.3.9.2. Market Size and Forecast, By Vaccine
    • 8.3.9.3. Market Size and Forecast, By Animal Type
    • 8.3.9.4. Market Size and Forecast, By End User
  • 8.3.10. Italy Brucellosis Vaccines Market
    • 8.3.10.1. Market Size and Forecast, By Type
    • 8.3.10.2. Market Size and Forecast, By Vaccine
    • 8.3.10.3. Market Size and Forecast, By Animal Type
    • 8.3.10.4. Market Size and Forecast, By End User
  • 8.3.11. Spain Brucellosis Vaccines Market
    • 8.3.11.1. Market Size and Forecast, By Type
    • 8.3.11.2. Market Size and Forecast, By Vaccine
    • 8.3.11.3. Market Size and Forecast, By Animal Type
    • 8.3.11.4. Market Size and Forecast, By End User
  • 8.3.12. Rest of Europe Brucellosis Vaccines Market
    • 8.3.12.1. Market Size and Forecast, By Type
    • 8.3.12.2. Market Size and Forecast, By Vaccine
    • 8.3.12.3. Market Size and Forecast, By Animal Type
    • 8.3.12.4. Market Size and Forecast, By End User
• 8.4. Asia-Pacific
  • 8.4.1. Key Market Trends and Opportunities
  • 8.4.2. Market Size and Forecast, By Type
  • 8.4.3. Market Size and Forecast, By Vaccine
  • 8.4.4. Market Size and Forecast, By Animal Type
  • 8.4.5. Market Size and Forecast, By End User
  • 8.4.6. Market Size and Forecast, By Country
  • 8.4.7. Japan Brucellosis Vaccines Market
    • 8.4.7.1. Market Size and Forecast, By Type
    • 8.4.7.2. Market Size and Forecast, By Vaccine
    • 8.4.7.3. Market Size and Forecast, By Animal Type
    • 8.4.7.4. Market Size and Forecast, By End User
  • 8.4.8. China Brucellosis Vaccines Market
    • 8.4.8.1. Market Size and Forecast, By Type
    • 8.4.8.2. Market Size and Forecast, By Vaccine
    • 8.4.8.3. Market Size and Forecast, By Animal Type
    • 8.4.8.4. Market Size and Forecast, By End User
  • 8.4.9. Australia Brucellosis Vaccines Market
    • 8.4.9.1. Market Size and Forecast, By Type
    • 8.4.9.2. Market Size and Forecast, By Vaccine
    • 8.4.9.3. Market Size and Forecast, By Animal Type
    • 8.4.9.4. Market Size and Forecast, By End User
  • 8.4.10. India Brucellosis Vaccines Market
    • 8.4.10.1. Market Size and Forecast, By Type
    • 8.4.10.2. Market Size and Forecast, By Vaccine
    • 8.4.10.3. Market Size and Forecast, By Animal Type
    • 8.4.10.4. Market Size and Forecast, By End User
  • 8.4.11. South Korea Brucellosis Vaccines Market
    • 8.4.11.1. Market Size and Forecast, By Type
    • 8.4.11.2. Market Size and Forecast, By Vaccine
    • 8.4.11.3. Market Size and Forecast, By Animal Type
    • 8.4.11.4. Market Size and Forecast, By End User
  • 8.4.12. Rest of Asia-Pacific Brucellosis Vaccines Market
    • 8.4.12.1. Market Size and Forecast, By Type
    • 8.4.12.2. Market Size and Forecast, By Vaccine
    • 8.4.12.3. Market Size and Forecast, By Animal Type
    • 8.4.12.4. Market Size and Forecast, By End User
• 8.5. LAMEA
  • 8.5.1. Key Market Trends and Opportunities
  • 8.5.2. Market Size and Forecast, By Type
  • 8.5.3. Market Size and Forecast, By Vaccine
  • 8.5.4. Market Size and Forecast, By Animal Type
  • 8.5.5. Market Size and Forecast, By End User
  • 8.5.6. Market Size and Forecast, By Country
  • 8.5.7. Brazil Brucellosis Vaccines Market
    • 8.5.7.1. Market Size and Forecast, By Type
    • 8.5.7.2. Market Size and Forecast, By Vaccine
    • 8.5.7.3. Market Size and Forecast, By Animal Type
    • 8.5.7.4. Market Size and Forecast, By End User
  • 8.5.8. Saudi Arabia Brucellosis Vaccines Market
    • 8.5.8.1. Market Size and Forecast, By Type
    • 8.5.8.2. Market Size and Forecast, By Vaccine
    • 8.5.8.3. Market Size and Forecast, By Animal Type
    • 8.5.8.4. Market Size and Forecast, By End User
  • 8.5.9. South Africa Brucellosis Vaccines Market
    • 8.5.9.1. Market Size and Forecast, By Type
    • 8.5.9.2. Market Size and Forecast, By Vaccine
    • 8.5.9.3. Market Size and Forecast, By Animal Type
    • 8.5.9.4. Market Size and Forecast, By End User
  • 8.5.10. Rest of LAMEA Brucellosis Vaccines Market
    • 8.5.10.1. Market Size and Forecast, By Type
    • 8.5.10.2. Market Size and Forecast, By Vaccine
    • 8.5.10.3. Market Size and Forecast, By Animal Type
    • 8.5.10.4. Market Size and Forecast, By End User

CHAPTER 9: COMPETITIVE LANDSCAPE

• 9.1. Introduction
• 9.2. Top Winning Strategies
• 9.3. Product Mapping of Top 10 Player
• 9.4. Competitive Dashboard
• 9.5. Competitive Heatmap
• 9.6. Top Player Positioning, 2023

CHAPTER 10: COMPANY PROFILES

• 10.1. Ceva Poultry
  • 10.1.1. Company Overview
  • 10.1.2. Key Executives
  • 10.1.3. Company Snapshot
  • 10.1.4. Operating Business Segments
  • 10.1.5. Product Portfolio
  • 10.1.6. Business Performance
  • 10.1.7. Key Strategic Moves and Developments
• 10.2. Colorado Serum Company
  • 10.2.1. Company Overview
  • 10.2.2. Key Executives
  • 10.2.3. Company Snapshot
  • 10.2.4. Operating Business Segments
  • 10.2.5. Product Portfolio
  • 10.2.6. Business Performance
  • 10.2.7. Key Strategic Moves and Developments
• 10.3. Creative Biolabs
  • 10.3.1. Company Overview
  • 10.3.2. Key Executives
  • 10.3.3. Company Snapshot
  • 10.3.4. Operating Business Segments
  • 10.3.5. Product Portfolio
  • 10.3.6. Business Performance
  • 10.3.7. Key Strategic Moves and Developments
• 10.4. CZ Vaccines
  • 10.4.1. Company Overview
  • 10.4.2. Key Executives
  • 10.4.3. Company Snapshot
  • 10.4.4. Operating Business Segments
  • 10.4.5. Product Portfolio
  • 10.4.6. Business Performance
  • 10.4.7. Key Strategic Moves and Developments
• 10.5. Fivet Animal Health
  • 10.5.1. Company Overview
  • 10.5.2. Key Executives
  • 10.5.3. Company Snapshot
  • 10.5.4. Operating Business Segments
  • 10.5.5. Product Portfolio
  • 10.5.6. Business Performance
  • 10.5.7. Key Strategic Moves and Developments
• 10.6. Hester Biosciences Limited
  • 10.6.1. Company Overview
  • 10.6.2. Key Executives
  • 10.6.3. Company Snapshot
  • 10.6.4. Operating Business Segments
  • 10.6.5. Product Portfolio
  • 10.6.6. Business Performance
  • 10.6.7. Key Strategic Moves and Developments
• 10.7. Indian Immunologicals Ltd
  • 10.7.1. Company Overview
  • 10.7.2. Key Executives
  • 10.7.3. Company Snapshot
  • 10.7.4. Operating Business Segments
  • 10.7.5. Product Portfolio
  • 10.7.6. Business Performance
  • 10.7.7. Key Strategic Moves and Developments
• 10.8. Jordan Bio-industries Center
  • 10.8.1. Company Overview
  • 10.8.2. Key Executives
  • 10.8.3. Company Snapshot
  • 10.8.4. Operating Business Segments
  • 10.8.5. Product Portfolio
  • 10.8.6. Business Performance
  • 10.8.7. Key Strategic Moves and Developments
• 10.9. Laboratories Tornel
  • 10.9.1. Company Overview
  • 10.9.2. Key Executives
  • 10.9.3. Company Snapshot
  • 10.9.4. Operating Business Segments
  • 10.9.5. Product Portfolio
  • 10.9.6. Business Performance
  • 10.9.7. Key Strategic Moves and Developments
• 10.10. Merck And Co., Inc.
  • 10.10.1. Company Overview
  • 10.10.2. Key Executives
  • 10.10.3. Company Snapshot
  • 10.10.4. Operating Business Segments
  • 10.10.5. Product Portfolio
  • 10.10.6. Business Performance
  • 10.10.7. Key Strategic Moves and Developments

관련자료